US Broker Ratings

GeneDx Holdings Corp. (WGS)

⚠️ No article content returned.

..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Healthcare Innovator with 32.92% Potential Upside

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a promising player in the biotechnology sector, is capturing the attention of investors with its innovative focus on eye care therapeutics and infectious disease prevention...

LivaNova PLC (LIVN) Stock Analysis: Navigating Growth in the Medical Devices Sector with a 6.8% Upside Potential

LivaNova PLC (NASDAQ: LIVN), a prominent player in the healthcare sector specializing in medical devices, continues to capture investor attention with its robust growth prospects and strategic market positioning. Headquartered..

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Powerhouse with 9.63% Potential Upside

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a promising player in the biotechnology sector, is capturing investor attention with its robust pipeline of therapies targeting rare and orphan diseases. Headquartered in Foster..

Certara, Inc. (CERT) Stock Analysis: Unraveling the 90.68% Upside Potential

Investors seeking opportunities in the healthcare sector should take a closer look at Certara, Inc. (NASDAQ: CERT), a pivotal player in the health information services industry. With a market capitalization..

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: A 13.45% Upside Potential in the Healthcare Sector

LeMaitre Vascular, Inc. (NASDAQ: LMAT) is carving a niche for itself in the healthcare landscape with its specialized focus on medical instruments and supplies. Headquartered in Burlington, Massachusetts, LeMaitre Vascular..

Metsera, Inc. (MTSR) Stock Report: Evaluating the Biotech Player’s -19.15% Potential Downside

Metsera, Inc. (NASDAQ: MTSR), a promising player in the biotechnology sector, has garnered attention from investors due to its innovative approach to tackling obesity and related diseases. As a clinical-stage..

BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Unveiling a Potential Upside of 179.68%

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) stands out as a compelling investment opportunity in the healthcare sector, specifically within the realm of drug manufacturers focused on specialty and generic pharmaceuticals. Based..

Merus N.V. (MRUS) Stock Analysis: Potential Upside in the Biotech Sector

Merus N.V. (NASDAQ: MRUS), a Dutch biotechnology company, is making waves in the healthcare sector with its innovative approach to immuno-oncology therapies. With a strategic focus on developing bispecific antibody..

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring a Remarkable 151% Potential Upside

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) presents a compelling opportunity for investors in the biotechnology sector, exhibiting a notable potential upside of 151.22% based on the average target price set by..

Vericel Corporation (VCEL) Stock Analysis: Potential 43.79% Upside in the Biotech Sector

Vericel Corporation (NASDAQ: VCEL) stands out in the biotechnology sector with a promising growth trajectory, especially given the company’s focus on innovative cellular therapies and biologic products. Specializing in sports..

QuidelOrtho Corporation (QDEL) Stock Analysis: Exploring a 63.60% Potential Upside in the Medical Devices Sector

QuidelOrtho Corporation (NASDAQ: QDEL), a prominent player in the healthcare sector, is capturing investor attention with its diagnostic testing solutions. As a key contender in the medical devices industry, QuidelOrtho’s..

Immunovant, Inc. (IMVT) Stock Analysis: Unpacking a 51% Potential Upside

Immunovant, Inc. (NASDAQ: IMVT) has captured investor attention with a promising 51.19% potential upside, as indicated by analyst target prices. As a clinical-stage immunology company, Immunovant is poised at the..

Privia Health Group, Inc. (PRVA) Stock Analysis: A Promising 44% Upside for Investors

Privia Health Group, Inc. (NASDAQ: PRVA) stands as a dynamic player in the healthcare sector, specifically within the health information services industry. With a market capitalization of $2.66 billion, Privia..

ImmunityBio, Inc. (IBRX): Harnessing a 407% Revenue Growth with a Promising 28% Upside Potential

ImmunityBio, Inc. (NASDAQ: IBRX), a pioneering player in the biotechnology sector, has been capturing investor attention with its robust revenue growth and promising stock performance. The company, headquartered in San..

Acadia Healthcare Company, Inc. (ACHC) Stock Analysis: Exploring a 7.68% Potential Upside

For investors considering the healthcare sector, Acadia Healthcare Company, Inc. (NASDAQ: ACHC) presents an intriguing opportunity. As a major player in providing behavioral healthcare services across the United States and..

MoonLake Immunotherapeutics (MLTX) Stock Analysis: Unveiling a 12.8% Potential Upside in Biotech Innovation

MoonLake Immunotherapeutics (NASDAQ: MLTX), a burgeoning biotechnology firm based in Switzerland, is making waves in the healthcare sector with its promising portfolio of treatments targeting inflammatory diseases. With a market..

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: A Potential 94% Upside Lures Investors

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), a biotechnology firm with a focus on rare endocrine diseases, is catching the eye of investors with its significant potential upside. Based in San Diego,..

Arcellx, Inc. (ACLX) Stock Analysis: Navigating Biotech Volatility with Strong Analyst Support

Arcellx, Inc. (NASDAQ: ACLX) is capturing the attention of investors in the biotech sector with its innovative immunotherapy developments. Headquartered in Redwood City, California, Arcellx focuses on creating treatments for..

Sotera Health Company (SHC) Stock Analysis: A 16.85% Potential Upside in Healthcare Diagnostics & Research

Sotera Health Company (NASDAQ: SHC) stands out in the healthcare sector, particularly in the diagnostics and research industry. With a market capitalization of $4.97 billion, the company has established itself..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds